Aligos Therapeutics, Inc. 8-K

What Happened
Aligos Therapeutics, Inc. filed an 8‑K on April 14, 2026 announcing first interim analysis results from the Phase 2 B‑SUPREME study of pevifoscorvir sodium in chronic hepatitis B (HBV) infection. For Part 2a (HBeAg‑ cohort), the independent Data Safety Monitoring Review Board (DSMB) recommended the study continue and supported increasing the sample size to improve statistical power; the cohort did not meet futility criteria. The company also announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to pevifoscorvir sodium, a CAM‑E capsid assembly modulator being developed for HBV.

Key Details

• Filing date: April 14, 2026 (Form 8‑K).
• Study: Phase 2 B‑SUPREME, Part 2a (HBeAg‑ cohort).
• DSMB action: Recommended continuation and increase in sample size; futility criteria not met.
• Regulatory: FDA granted Fast Track designation to pevifoscorvir sodium.

Why It Matters
The DSMB recommendation to continue and expand the HBeAg‑ cohort indicates the interim data did not trigger stopping for futility, allowing Aligos to gather more data to better evaluate efficacy and safety. FDA Fast Track designation can facilitate more frequent communication with the agency and may accelerate development and review pathways for pevifoscorvir, which is material for investors monitoring the company’s HBV program timeline. The filing contains no new financial results or guidance.